PRICE T ROWE ASSOCIATES INC /MD/ - CYTOMX THERAPEUTICS INC ownership

CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 111 filers reported holding CYTOMX THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 1.49 and the average weighting 0.0%.

Quarter-by-quarter ownership
PRICE T ROWE ASSOCIATES INC /MD/ ownership history of CYTOMX THERAPEUTICS INC
ValueSharesWeighting
Q2 2022$1,159,000
-34.3%
633,418
-4.2%
0.00%
Q1 2022$1,765,000
-38.2%
661,063
+0.2%
0.00%
Q4 2021$2,857,000
-15.3%
659,863
-0.4%
0.00%
Q3 2021$3,373,000
-22.6%
662,665
-3.7%
0.00%
Q2 2021$4,357,000
-66.8%
688,324
-59.4%
0.00%
-100.0%
Q1 2021$13,112,000
+191.6%
1,696,266
+147.1%
0.00%
Q4 2020$4,496,000
-1.5%
686,474
-0.0%
0.00%
-100.0%
Q3 2020$4,566,000
-20.2%
686,6740.0%0.00%0.0%
Q2 2020$5,720,000
+8.6%
686,674
+0.0%
0.00%0.0%
Q1 2020$5,265,000
-7.7%
686,398
+0.0%
0.00%0.0%
Q4 2019$5,702,000
-65.0%
686,188
-68.9%
0.00%
-50.0%
Q3 2019$16,274,000
-48.2%
2,205,101
-21.3%
0.00%
-50.0%
Q2 2019$31,426,000
-5.4%
2,800,872
-9.4%
0.00%
-20.0%
Q1 2019$33,225,000
-46.2%
3,090,673
-24.5%
0.01%
-50.0%
Q4 2018$61,782,000
-18.3%
4,091,526
+0.1%
0.01%
-9.1%
Q3 2018$75,621,000
+1.8%
4,087,603
+25.8%
0.01%0.0%
Q2 2018$74,283,000
-9.1%
3,249,464
+13.1%
0.01%
-15.4%
Q1 2018$81,721,000
+800.1%
2,872,432
+567.9%
0.01%
+1200.0%
Q4 2017$9,079,000
+61.1%
430,087
+38.7%
0.00%0.0%
Q3 2017$5,634,000
+49.8%
310,083
+27.8%
0.00%0.0%
Q2 2017$3,762,000
+46.9%
242,690
+63.6%
0.00%
Q1 2017$2,561,000
+15.8%
148,305
-26.3%
0.00%
Q4 2016$2,211,000
+1345.1%
201,203
+1241.4%
0.00%
Q2 2016$153,00015,0000.00%
Other shareholders
CYTOMX THERAPEUTICS INC shareholders Q4 2021
NameSharesValueWeighting ↓
Aquilo Capital Management, LLC 524,763$7,924,0003.84%
Congress Park Capital LLC 123,311$1,862,0002.05%
Perceptive Advisors 2,911,715$43,588,0001.66%
RTW INVESTMENTS, LP 908,586$13,720,0001.28%
HAMILTON LANE ADVISORS LLC 68,753$1,038,0000.91%
HARBOURVEST PARTNERS LLC 79,193$1,196,0000.57%
SPHERA FUNDS MANAGEMENT LTD. 273,151$4,125,0000.46%
Exane Asset Management 50,000$755,000,0000.44%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 622,548$9,400,0000.38%
Cormorant Asset Management, LP 296,712$4,480,0000.36%
View complete list of CYTOMX THERAPEUTICS INC shareholders